International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry. Types I, II and III PPB
|
|
- Iris Scott
- 5 years ago
- Views:
Transcription
1 CHILDREN S HOSPITALS AND CLINICS of MINNESOTA 2525 Chicago Avenue South Minneapolis, Minnesota 55404, USA International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry Types I, II and III PPB APPENDIX VIII: TYPE II AND IIII PPB HYDRATION, TREATMENT GUIDELINES, AND ROADMAPS Pre-hydration for ADo courses: D5½NS at 200 ml/m2/hour, until patient is adequately hydrated (urine output exceeds 2 cc/kg/hr). Chemotherapy: Vincristine push day 1, then weekly until (including) week 7 then every 3 weeks. Actinomycin push day 1. Ifosfamide (I) over 3 hours, days 1, 2. MESNA with Ifosfamide and then 3, 6, and 9 hours after the start of the Ifosfamide dose. Doxorubicin over 30 min, days 1, 2. Pre-hydration for A courses: D5½NS at 200 ml/m2/hour, until patient is adequately hydrated (urine output exceeds 2 cc/kg/hr). Chemotherapy: Vincristine push day 1. Actinomycin push day 1. Ifosfamide (I) over 3 hours, day 1. MESNA with Ifosfamide and then 3, 6, and 9 hours after the start of the Ifosfamide dose. Post-hydration, all courses: D5½NS + 10 meq KCl/L at 125 ml/m2/hour beginning immediately after Ifosfamide and continuing until next Ifosfamide dose or until 24 hours after last dose.
2 Treatment Study Therapy: I 2 VADo 2 Courses 1 & 2 BSA m² Due Given Day Week VCR *IFOS DACT DOXO Mesna mg. 1 1 VCR *IFOS DACT DOXO Mesna 2 *IFOS DOXO 8 2 VCR 15 3 VCR 22 4** VCR *IFOS DACT DOXO Mesna 23 *IFOS DOXO 29 5 VCR 36 6** VCR Vincristine (VCR) Actinomycin D (DACT) Doxorubicin (DOXO) Dose Table DOXO: Mesna: < 6 months 15 mg/m² Dose per Table, push Days as above Dose per Table, over 3 hours, Days as above. Give with Mesna and hydration. Dose per Table, push Days as above Dose per Table, 6-hr continuous infusion, Days as above (Max. cumulative dose 375 mg/m² if no mediastinal radiation; max dose 300 mg/m² if mediastinal radiation used). Dose per Table, with Ifos over 1 hour; doses 2 and 3 push over 3-5 min. at hours 3 and mg/m² 30 mg/m² 300 mg/m² 400 mg/m² *Substitute CPM for IFOS for all subsequent cycles if significant Fanconi syndrome occurs. See Protocol A-XI: 1.2 for CPM, and
3 Treatment Study Therapy: I 2 VADo 2 Courses 3 & 4 BSA m² Due Given Day Week VCR *IFOS DACT DOXO Mesna mg. 1 7 VCR *IFOS DACT DOXO Mesna 2 *IFOS DOXO VCR 8 8 VCR * VCR *IFOS DACT DOXO Mesna 23 *IFOS DOXO VCR 36 12** VCR **Begin next course when Plt. Ct. > 100k and ANC > 1,000. Vincristine (VCR) Actinomycin D (DACT) Doxorubicin (DOXO) Dose Table DOXO: Mesna: < 6 months 15 mg/m² Dose per Table, push Days as above Dose per Table, over 3 hours, Days as above. Give with Mesna and hydration. Dose per Table, push Days as above Dose per Table, 6-hr continuous infusion, Days as above (Max. cumulative dose 375 mg/m² if no mediastinal radiation; max dose 300 mg/m² if mediastinal radiation used). Dose per Table, with Ifos over 1 hour; doses 2 and 3 push over 3-5 min. at hours 3 and mg/m² 30 mg/m² 300 mg/m² 400 mg/m² *Substitute CPM for IFOS for all subsequent cycles if significant Fanconi syndrome occurs. See Protocol A-XI: 1.2 for CPM, and
4 Therapy: A Courses 5 & ** VCR *IFOS DACT Mesna 22 16** VCR *IFOS DACT Mesna Vincristine (VCR) Dose per Table, push Days as above Dose per Table, over 3 hours, Days as above. Give with Mesna and hydration. Actinomycin D (DACT) Dose per Table, push Days as above Dose per Table, with Ifos over 1 hour; doses 2 and 3 push over 3-5 min. at hours 3 and 7. M: 300 mg/m² 400 mg/m²
5 Therapy: A Courses 7 & * VCR *IFOS DACT Mesna 22 22* VCR *IFOS DACT Mesna Vincristine (VCR) Dose per Table, push Days as above Dose per Table, over 3 hours, Days as above. Give with Mesna and hydration. Actinomycin D (DACT) Dose per Table, push Days as above Dose per Table, with Ifos over 1 hour; doses 2 and 3 push over 3-5 min. at hours 3 and 7. M: 300 mg/m² 400 mg/m²
6 Therapy: A Courses 9 & * VCR *IFOS DACT Mesna 22 28* VCR *IFOS DACT Mesna Vincristine (VCR) Dose per Table, push Days as above Dose per Table, over 3 hours, Days as above. Give with Mesna and hydration. Actinomycin D (DACT) Dose per Table, push Days as above Dose per Table, with Ifos over 1 hour; doses 2 and 3 push over 3-5 min. at hours 3 and 7. M: 300 mg/m² 400 mg/m²
7 Therapy: A Courses 11 & ** VCR *IFOS DACT Mesna 22 34** VCR *IFOS DACT Mesna Begin Follow up Vincristine (VCR) Dose per Table, push Days as above Dose per Table, over 3 hours, Days as above. Give with Mesna and hydration. Actinomycin D (DACT) Dose per Table, push Days as above Dose per Table, with Ifos over 1 hour; doses 2 and 3 push over 3-5 min. at hours 3 and 7. M: 300 mg/m² 400 mg/m²
ANAPLASTIC LARGE CELL LYMPHOMA TREATMENT ROAD MAP (Modified ALCL99)
ANAPLASTIC LARGE CELL LYMPHOMA TREATMENT ROAD MAP (Modified ALCL99) CLASSIFICATION OF TREATMENT GROUPS: 1. Isolated Skin lesions, < 5 skin lesions. Treatment course: ( No treatment, wait and see approach)
More informationSAALT3W Sarcoma Dr. Meg Knowling. Protocol Code Tumour Group Contact Physician
BCCA Protocol Summary for Etoposide, Ifosfamide-Mesna (SAIME) Alternating with vincristine, DOXOrubicin and Cyclophosphamide (with or without Mesna)(SAVAC or SAVACM) with Filgrastim Support at a THREE
More informationZzbeacon,Zayna [MR ]
AALL1131 INTERIM MAINTENANCE, HR-ALL, ARM B, HD MTX Properties Cycle 1 9/27/2012 through 11/28/2012 (63 days), Planned Day 1, Cycle 1 Planned for 9/27/2012 Release CBC and differential Release Release
More informationVincristine Ifosfamide Doxorubicin Etoposide (VIDE) Sarcoma
Systemic Anti Cancer Treatment Protocol Vincristine Ifosfamide Doxorubicin Etoposide (VIDE) Sarcoma PROTOCOL REF: MPHAVIDE (Version No: 1.0) Approved for use in: Ewings sarcoma Desmoplastic small round
More informationDoxorubicin and Ifosfamide Sarcoma
Systemic Anti Cancer Treatment Protocol Doxorubicin and Ifosfamide Sarcoma PROTOCOL REF: MPHADOXIFO (Version No:.0) Approved for use in: Soft tissue sarcoma Dosage: Drug Dosage Route Frequency Doxorubicin
More information1. FBE,UEC, LFT 2. USS of eyes confirm intraocular origin, possible calcifications. 3. CT(if available) of eyes and head
Retinoblastoma PNG V2 Treatment Guidelines for PNG Retinoblastoma 01V1 Current aim of treatment is to preserve life, vision preservation is secondary at this time. Retinoblastoma remains intra ocular and
More informationPREHYDRATION: 1000 ml NS with potassium chloride 20 meq and magnesium sulphate 2 g IV over 1 hour prior to CISplatin
BC Cancer Protocol Summary for Treatment of Newly Diagnosed Nasal, Extranodal Natural Killer (NK) or T-cell lymphoma, using Concurrent Radiation and weekly CISplatin followed by Etoposide, Ifosfamide,
More informationLYIVAC (Magrath B) + R (rituximab) [To be used after LYCODOX-M (Magrath A) + R]
Page 1 of 7 PPO FOR THE TREATMENT OF BURKITT LYMPHOMA AND LEUKEMIA LYIVAC (Magrath B) + R (rituximab) [To be used after LYCODOX-M (Magrath A) + R] DAY DATE CHEMOTHERAPY 1 Start signature sheet and prednisolone
More informationCisplatin Doxorubicin Sarcoma
Systemic Anti Cancer Treatment Protocol Cisplatin Doxorubicin Sarcoma PROCEDURE REF: MPHACISDOX (Version No. _1.0) Approved for use in: Osteosarcoma Palliative / advanced disease Not suitable for PAM schedule
More informationGemcitabine + Cisplatin Regimen
Gemcitabine + Cisplatin Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication
More informationPediatric Acute Lymphoblastic Leukemia Protocol 2008 (PALL08)
Pediatric Acute Lymphoblastic Leukemia Protocol 2008 (PALL08) Department of Pediatric Hematology/Oncology King Fahd National Centre for Children s Cancer and Research King Faisal Specialist Hospital and
More informationNB. This version combines both previous inpatient and ambulatory protocols. See DRUG REGIMEN section for details.
DA- INDICATION High grade lymphoma. Omit rituximab if CD20 negative. NB. This version combines both previous inpatient and ambulatory protocols. See DRUG REGIMEN section for details. TREATMENT INTENT Curative
More informationThis is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21
R- / INDICATION Lymphoma Histiocytosis Omit rituximab if CD20-negative. TREATMENT INTENT Disease modification or curative depending on clinical circumstances PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationULYRICE. Protocol Code. Lymphoma. Tumour Group. Dr. Laurie Sehn. Contact Physician
BCCA Protocol Summary for the Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and rituximab Protocol Code Tumour Group
More informationDA-EPOCH-R (Etoposide/Inpatient)
DA- (Etoposide/Inp) INDICATION High grade lymphoma. Omit rituximab if CD20 negative. PRE-ASSESSMENT 1. Ensure histology is confirmed prior to administration of chemotherapy and document in notes. 2. Record
More informationCisplatin Vinorelbine (Oral) therapy +/- radiotherapy
1 REGIMEN TITLE: Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy Page 1 of 5 Indication: First line in Radical/ Induction, Adjuvant and Advanced & Palliative treatment of Non-small cell lung cancer
More informationNetwork Chemotherapy Regimens
Thames Valley Network Chemotherapy Regimens Urological Cancer Network Chemotherapy Protocols Urological Cancer 1 Notes from the editor Thames Valley These protocols are available on the Network website
More informationWeekly Cisplatin + Radiotherapy - Interlace study -
Weekly Cisplatin + Radiotherapy - Interlace study - A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with
More informationMedical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia
Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)
More informationOriginal Article Clinical analysis of pleuropulmonary blastoma in four larger Chinese pediatric hematology and oncology center
Int J Clin Exp Med 2016;9(9):18168-18175 www.ijcem.com /ISSN:1940-5901/IJCEM0027430 Original Article in four larger Chinese pediatric hematology and oncology center Xiaoli Ma 1,2,3, Xisi Wang 1,2,3, Xiaofei
More informationChemotherapy dosing in pediatric patient. Surapon Wiangnon Suddhavej Hospital Faculty of Medicine Mahasarakham University
Chemotherapy dosing in pediatric patient Surapon Wiangnon Suddhavej Hospital Faculty of Medicine Mahasarakham University Outline Principle of chemotherapy Use of BSA in chemotherapy dosing Pharmacokinetic
More informationCISPLATIN Chemo-radiation regimen Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol CISPLATIN Chemo-radiation regimen Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIX (Version No: 1.0) Approved for use in: Locally advanced cervical cancer (adjuvant/curative)
More informationAdjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens. High Grade Lymphoma
Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens The following table lists the evidence-informed regimens (both IV and non-iv) for high grade and Burkitt s lymphoma used in the
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME R-IVE.DOC CONTROLLED DOC NO: HCCPG B53 CSIS Regimen Name: R-IVE. R-IVE Regimen
R-IVE Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Relapsed/ refractory
More informationR-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement)
R-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement) Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case
More informationELIGIBILITY: small cell or neuroendocrine cancer (pure or mixed) administration of this protocol is restricted to BCCA Cancer Centres
BCCA Protocol Summary for Treatment of Small Cell or Neuroendocrine Carcinoma of Gynecologic System Origin using PACLitaxel, CISplatin, Etoposide and CARBOplatin with Radiation (GO 95 02) Protocol Code:
More informationNECN CHEMOTHERAPY HANDBOOK PROTOCOL
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate 1* to 5 Prednisolone 40mg/m 2 Oral Once Daily For 5 days 1 Paracetamol 1gram Oral Once Only Chlorphenamine 10mg IV bolus Ondansetron 8mg IV
More informationALCL 99. International protocol for the treatment of childhood anaplastic large cell lymphoma
ALCL 99 International protocol for the treatment of childhood anaplastic large cell lymphoma November 1999 1. BACKGROUND...4 1.1. RESULTS OF THE DIFFERENT EUROPEAN NATIONAL PROTOCOLS...4 1.1.1. BFM studies...4
More informationX M/ (R) Dose adjusted (DA)-EPOCH-R
X M/ (R) adjusted (DA)-EPOCH-R Indication High-risk CD20+ diffuse large B cell lymphoma especially C-MYC and BCL-2 activated (i.e. double hit lymphoma) and mediastinal sclerosing (thymic) large B cell
More informationClinical Management Guideline for Small Cell Lung Cancer
Diagnosis and Staging: Key Points 1. Ensure a CT scan that is
More informationTIP Paclitaxel, Ifosfamide and Cisplatin
Systemic Anti Cancer Treatment Protocol TIP Paclitaxel, Ifosfamide and Cisplatin PROTOCOL REF: MPHATIPGC (Version No: 1.0) Approved for use in: Second line treatment of germ cell tumours Dosage: Drug Dosage
More informationPVACE-BOP (Hodgkin s Lymphoma)
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate 1 Ondansetron 8mg IV / Oral vinblastine 6mg/m 2 (Max: 10mg) IV Infusion Etoposide 100mg/m 2 IV infusion Patients over 65 years by 15 min infusion
More informationVIP (Etoposide, Ifosfamide and Cisplatin)
VIP (Etoposide, Ifosfamide and Cisplatin) Indication First line treatment for metastatic seminoma, non seminoma or combined tumours where bleomycin is contra-indicated. Usually used for patients with intermediate
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second cancer
More informationECX. Anti-emetics: Day 1: highly emetogenic Days 2 21: mildly emetogenic
Page 1 of 5 As an alternative to ECF: For locally advanced (inoperable) or metastatic oesophageal or gastric cancer; peri-operative use in oesophageal or gastric cancer; adenocarcinoma of unknown primary
More informationBurn Resuscitation Formulas. John P. Sabra, MD Seton Surgical Group Department of Surgery Dell Medical School Austin, TX
Burn Resuscitation Formulas John P. Sabra, MD Seton Surgical Group Department of Surgery Dell Medical School Austin, TX BURN INJURY % Physiologic Change % TBSA burn Stasis BURN VASCULAR PERMEABILITY
More informationMr Hrouda Date Review date: May 2014
GERM CELL TUMOURS Section by: Dr Philip Savage, Dr Cathryn Brock and Professor Michael Seckl Version: Germ Cell Tumour Regimens v3.02 NWLCN 28May12 Section last updated: 28 th May 2012 Last Corrected 28
More informationChemotherapy Teaching Points
Chemotherapy Teaching Points 1. Antimetabolites - These drugs are analogs of vital co-factors in DNA or RNA synthesis. They competitively inhibit DNA or RNA production, or are directly incorporated into
More informationVasospasm and cardiac ischemia (Type 3 ) Hypertension Hypotension Arrhythmias Miscellaneous ( pericardial inflammation, valvular abnormalities )
Management of Cardiotoxicity due to Systemic Cancer Therapy Left Ventricular Dysfunction Type 1 cardiac dysfunction Type 2 cardiac dysfunction Vasospasm and cardiac ischemia (Type 3 ) Hypertension Hypotension
More informationCase Report Iran J Ped Hematol Oncol. 2016, Vol 7.No 1, Pleuropulmonary blastoma: report of 2 cases
Case Report Iran J Ped Hematol Oncol. 2016, Vol 7.No 1, 63-67 Pleuropulmonary blastoma: report of 2 cases Nahid Reisi MD 1,*, Saeed Yosefian MD 2, Pardis Namatollahi MD 3 1. Pediatric Oncologist, Associate
More informationGemcitabine & Cisplatin
Gemcitabine & Cisplatin Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Advanced
More information1.28 Protocol Name: CODOX-M/IVAC
1.28 Protocol Name: CODOX-M/IVAC Indication Burkitt's or Burkitt's-like lymphoma - especially those with 1 of the following poor risk criteria: Lymphoblastic lymphoma - especially B subtype Acute Myeloid
More informationDRUG EXTRAVASATION. Vesicants. Irritants
DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)
More informationSUMMARY OF CHANGES Amendment 5, Version Date: March 24, 2010 Broadcast: 4/6/10
Amendment 5, Version Date: March 24, 2010 Broadcast: 4/6/10 RTOG 0239, "A Phase II Study Of Accelerated High Dose Thoracic Irradiation With Concurrent Chemotherapy For Patients With Limited Small Cell
More informationPatient: Becky Smith DOB: 01/26/XXXX Age: 5 y/o Attending: Dr. D. Miles Allergies: NKA MR#: 203. Patient Chart #203 Becky Smith
Patient Chart #203 Becky Smith 1 Property of CSCLV CSCLV Rev: 06/04/2018 Chief Complaint: Abdominal pain. Informant: Parents. HISTORY & PHYSICAL HPI: Ill looking patient, healthy until 2 days ago when
More informationTHE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST
Outpatient Anti Cancer Treatment Handbook LCV Lomustine, Cisplatin, Vincristine Packer Regimen Repeated every 6 weeks for a maximum of 6 cycles Approved for use in: Medulloblastoma adjuvant therapy Dosage:
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationADULT Updated: September 4, 2018
Updated: September 4, 2018 Regimen Reference Order ARIA: LYMP [R-CHOP alt. R-DHAP] Planned Course: Indication for Use: Every 21 days for 6 cycles (R-CHOP given on cycles 1, 3 and 5; R-DHAP given on cycles
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More information(R) CODOX M / (R) IVAC
(R) CODOX M / (R) IVAC Indication Burkitt's or Burkitt's-like lymphoma, especially those with 1 or more of the following poor risk criteria: - Raised LDH level - WHO performance status 2-4 - Ann Arbor
More informationNICaN Testicular Germ Cell Tumours SACT protocols
Reference No: Title: Author(s) Ownership: Approval by: Systemic Anti-Cancer Therapy (SACT) Guidelines for Germ Cell Tumours Dr Audrey Fenton Consultant Medical Oncologist, Dr Vicky Coyle Consultant Medical
More informationCD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated
INDICATION CD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated TREATMENT INTENT Curative or Disease Modification. PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationStandard Regimens for Haematology
Regimens for Haematology ChlVPP Chlorambucil 6mg/m 2 PO D1 to 14 Vinblastine 6mg/m 2 (max 10mg) IV on D1 & 8 Procarbazine 100mg/m 2 PO on D1 to 14 Prednisolone 40mg PO D1 to 14 ABVD Doxorubicin 25mg/m
More informationApplying CPT and HCPCS C-Codes and Rules for Drug Administration Services to Clinical Scenarios
Applying CPT and HCPCS C-Codes and Rules for Drug Administration Services to Clinical Scenarios IMPORTANT PLEASE READ The information provided in this handout is informational only and should not be taken
More informationZzbeacon,Zayna [MR ]
AALL1131-DS INDUCTION HR-ALL, DAYS 1-14 Properties Cycle 1 9/27/2012 through 10/10/2012 (14 days), Planned Day 1, Cycle 1 Planned for 9/27/2012 Release Labs CBC and differential Release Release Comprehensive
More informationPoor-prognostic advanced Germ Cell Tumors
14-10-16 Poor-prognostic advanced Germ Cell Tumors Karim Fizazi, MD, PhD Institut Gustave Roussy, France Metastatic GCT: Prognosis (IGCCC) Good prognosis Intermediate prognosis Poor prognosis J Clin Oncol
More informationTIP: Paclitaxel / Ifosfamide / Cisplatin in Relapsed Germ Cell Tumour
TIP: Paclitaxel / Ifosfamide / Cisplatin in Relapsed Germ Cell Tumour Indication: Second line therapy in Relapsed Germ Cell Tumours Regimen details: Paclitaxel 175mg/m 2 IV Cisplatin 20mg/m 2 IV - D5 Ifosfamide
More informationALL MAINTENANCE (25-60 years)
ALL MAINTENANCE (25-60 years) INDICATION Adult Acute Lymphoblastic Leukaemia (ALL) in remission not eligible for allogeneic transplantation This protocol is suitable for patients aged 25-60 years. It may
More informationPage Treatment Options by IGCCC Prognostic Group Adjuvant Carboplatin 7AUC CTIS: BEP 5 day D CTIS: 817 3
GERM CELL TUMOURS Section by: Dr Philip Savage and Professor Michael Seckl Version: Germ Cell Tumour Regimens Approved 4.02 NWLCN 29Oct13 Section last updated: 17 th October 2013 Last Corrected: 29 th
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME SMILE.DOC CONTROLLED DOC NO: HCCPG B57 CSIS Regimen Name: SMILE. SMILE chemotherapy
SMILE chemotherapy Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Extranodal
More informationBurkitt s Lymphoma or DLBCL with adverse features PATIENTS WITH GOOD PERFORMANCE STATUS
Regimen R-CODOX M Indication Burkitt s Lymphoma or DLBCL with adverse features Therapeutic Intent Radical/Curative PATIENTS WITH GOOD PERFORMANCE STATUS Day Medication Dose Route Administration Details
More informationStRs and CT doctors in haematology. September Folinic acid dose modified.
High dose Methotrexate and folinic acid rescue Full Title of Guideline: Author (include email and role): Division & Speciality: Clinical Guideline Review Date September 2018 GUIDELINE FOR THE USE OF HIGH
More informationPhysician Orders PEDIATRIC: LEB Stroke Admit Plan
Initiate Orders Phase Care Sets/Protocols/PowerPlans Initiate Powerplan Phase Phase: LEB Stroke Admit Phase. When to Initiate: LEB Stroke Admit Phase Admission/Transfer/Discharge Patient Status Initial
More informationALL CONSOLIDATION- Cycle 3 (25-60 years)
ALL CONSOLIDATION- (25-60 years) INDICATION Adult Acute Lymphoblastic Leukaemia (ALL) in remission not eligible for allogeneic transplantation This protocol is suitable for patients aged 25-60 years. It
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationIAWS-1/2 1. REGISTRY SYNOPSIS APPLICANT/COORDINATING INVESTIGATOR TITLE OF STUDY CONDITION OBJECTIVE(S) KEY INCLUSION AND Key inclusion criteria:
IAWS-1/2 1. REGISTRY SYNOPSIS APPLICANT/COORDINATING INVESTIGATOR TITLE OF STUDY CONDITION Professor Dr. med. J.T. Hartmann Comprehensive Cancer Center North, Dept. Hematology and Medical Oncology Universitätsklinikum
More informationCisplatin / Paclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Cisplatin / Paclitaxel Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIP (Version No: 1.0) Approved for use in: First line treatment for stage Ib-IV with minimal residual
More information2.07 Protocol Name: CHOP & Rituximab
2.07 Protocol Name: CHOP & Rituximab Indication Intermediate and high grade, B-cell non-hodgkins lymphoma expressing CD20. Second or third line therapy for low grade, B cell non- Hodgkins lymphoma expressing
More informationFAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated
Page 1 of 5 COG-AEWS1221: Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly
More informationManagement of Stage Ic-IV Malignant Ovarian Germ Cell Tumours
Management of Stage Ic-IV Malignant Ovarian Germ Cell Tumours Michael J Seckl Charing Cross Hospital Campus of Imperial College NHS Healthcare Trust Imperial College London, UK 9-12th June 2010 Caravaggio
More informationTherapeutic Algorithms in systemic sarcoma therapy
Therapeutic Algorithms in systemic sarcoma therapy Ian Judson Sarcoma Unit Royal Marsden Hospital What evidence do we have? What sorts of evidence are there? Experience personal, peers ( Bayesian ) Educational
More informationPresent status and future direction of clinical trials in advanced endometrial carcinoma
J Gynecol Oncol Vol. 9, No. 3:57-6, September 8 DOI:.38/jgo.8.9.3.57 Review Article Present status and future direction of clinical trials in advanced endometrial carcinoma Division of Gynecologic Oncology,
More informationSAMPLE. Survivorship Care Plan for Lymphoma (Diffuse Large B-Cell) General Information. Care team
SAMPLE This Survivorship Care Plan will facilitate cancer care following active treatment. It may include important contact information, a treatment summary, recommendations for follow-up care testing,
More informationCarboplatin and Gemcitabine
Systemic Anti Cancer Treatment Protocol Carboplatin and Gemcitabine PROTOCOL REF: MPHACAGELU (Version No: 1.0) Approved for use in: Advanced non-small cell lung cancer Performance status: 0 to 2 Re-challenge
More informationVIDE. Vincristine given via intravenous (IV) infusion over 10 minutes Etoposide & doxorubicin given together via IV infusion over 4 hours
VIDE VIDE This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for others it may
More informationFEC-D with HP Fluorouracil, Epirubicin, Cyclophosphamide, Followed by Docetaxel, Trastuzumab, Pertuzumab Neoadjuvant Protocol
Approved for use in: Neoadjuvant breast cancer: The neoadjuvant treatment of HER2 positive locally advanced, inflammatory or early breast cancer at high risk of recurrence Interim CDF funding from November
More informationVDC IE. Your treatment You will have 14 cycles of VDC IE given every 2 to 3 weeks.
VDC IE VDC IE This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for others
More informationTesticular Cancer. J. Richard Auman, MD. James J. Stark, MD. Jerry Singer, MD. September 19, 2008
Testicular Cancer J. Richard Auman, MD James J. Stark, MD Jerry Singer, MD September 19, 2008 Testicular Cancer From mystery to far-advanced disease: a remarkable case Case Presentation. 23 y. o. male
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Yescarta) Reference Number: CP.PHAR.XX Effective Date: 10.31.17 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 09.26.17 Last Review Date: 11.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder
More informationHodgkin s Lymphoma (Hodgkin s Disease, HD) PI HD-1 Protocol
1 Hodgkin s Lymphoma (Hodgkin s Disease, HD) PI HD-1 Protocol NCCN Pacific Island Working Group Clinical Members Scott Macfarlane Peter Bradbeer Jane Skeen Rob Corbett Radhika Sandilya PI HD-1 Updated
More informationCADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness
CADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness Service Line: Rapid Response Service Version: 1.0 Publication Date: August
More informationType Days HRG Procurement 1 Cost and Volume Delivery 1 Day case. Weekly for 30 weeks. 1-14inc Capecitabine 1250mg/m² twice daily
Colorectal - Adjuvant Standard adjuvant therapy for Duke's C Day(s) Drug Dose Route Comments and high risk Duke's B Colorectal cancer 5-FU/FA Weekly 1 Folinic acid 50mg IV IV Bolus injection via fast running
More informationCom cal fer la primera maniobre terapèutica en els sarcomes d extremitats. Tractament sistèmic.
Com cal fer la primera maniobre terapèutica en els sarcomes d extremitats. Tractament sistèmic. Dr. Javier Martín Broto Oncología Médica. HU Son Espases. Palma www.cotmes.com DIAGNOSTIC PROCEDURE: CRUCIAL
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Tisagenlecleucel (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at
More informationNCCP Chemotherapy Regimen. Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLItaxel (175) 14 day Therapy (DD AC-T)
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLItaxel (175) 14 day Therapy (DD AC-T) Note: There is an option for DOXOrubicin, cyclophosphamide followed by weekly PACLItaxel
More informationTHE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane
Systemic Anti Cancer Treatment Protocol EDP + mitotane PROCEDURE REF: MPHAHANEDP (Version No: 1.0) Approved for use in: Symptomatic treatment for advanced (unresectable, metastatic or relapsed) adrenocortical
More informationBurkitt lymphoma, double hit lymphoma or high IPI diffuse large B-cell lymphoma.
INDICATION Burkitt lymphoma, double hit lymphoma or high IPI diffuse large B-cell lymphoma. TREATMENT INTENT Curative. PRE-ASSESSMENT 1. Ensure histology is confirmed prior to administration of chemotherapy
More informationBCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide
BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin Cyclophosphamide Protocol Code Tumour Group Contact Physician BRAJFEC Breast Dr. Susan Ellard ELIGIBILITY: Patients
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationThe Prognostic Value of Initial Tumor Size in Patients with Ewing Family of Tumors
Original Article The Prognostic Value of Initial Tumor Size in Patients with Ewing Family of Tumors Rajeeb Kumar Deo 1, Prakash Chitalkar 2, Amit Joshi 1, Sushil Ranamagar 1 1 Department of Medicine, Shree
More informationWhat is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin
What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin Alison Moskowitz, MD Assistant Attending, Lymphoma Service Memorial Sloan Kettering
More informationMultivariate analysis of risk factors for cisplatin-induced nephrotoxicity in gynecological cancer
doi:10.1111/jog.13457 J. Obstet. Gynaecol. Res. Vol. 43,. 12: J. 1880 1886, Obstet. Gynaecol. December Res. 2017 Multivariate analysis of risk factors for cisplatin-induced nephrotoxicity in gynecological
More informationCisplatin and Gemcitabine Bladder Cancer: Full and split dose
Systemic Anti Cancer Treatment Protocol Cisplatin and Gemcitabine Bladder Cancer: Full and split dose PROCTOCOL REF: MPHAUROCIG (Version No: 1.0) Approved for use in: Neoadjuvant and palliative indications
More informationBCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and DOCEtaxel
BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin Cyclophosphamide DOCEtaxel Protocol Code Tumour Group Contact Physician BRAJFECD Breast Dr. Stephen Chia ELIGIBILITY:
More informationNCCP Chemotherapy Regimen
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) Note: There is an option for Dose Dense DOXOrubicin, cyclophosphamide PACLitaxel (DD AC T) therapy described
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME R-CODOX-M.DOC CONTROLLED DOC NO: HCCPG B115 CSIS Regimen Name: R-CODOXM. Rituximab + CODOX-M
Rituximab + CODOX-M Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Burkitt
More information5-FU & Cisplatin + Cetuximab
5-FU & Cisplatin + Cetuximab Available for Routine Use in Not routinely commissioned, each case requires prior documented approval before offering & commencing therapy from either: a) the relevant PCT
More information